Chardan Capital Sticks to Their Buy Rating for Kodiak Sciences (KOD)

Chardan Capital analyst Daniil Gataulin maintained a Buy rating on Kodiak Sciences (KODResearch Report) today and set a price target of $18.00. The company’s shares opened today at $10.91.

Gataulin covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Applied Genetic Technologies, and Kodiak Sciences. According to TipRanks, Gataulin has an average return of -0.1% and a 60.00% success rate on recommended stocks.

Kodiak Sciences has an analyst consensus of Hold, with a price target consensus of $11.43, a 4.77% upside from current levels. In a report released yesterday, Truist Financial also maintained a Buy rating on the stock with a $15.00 price target.

See the top stocks recommended by analysts >>

KOD market cap is currently $567.3M and has a P/E ratio of (1.82).

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KOD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Read More on KOD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More